Using Mycelium for a Sustainable Future feat. Kimberly Carlson
In this episode, David talks with Kimberly Carlson, CEO & CFO of Mushrooms Inc., a company that is aiming to bring forth a new era of sustainability with the use of mycelium.
Similar Posts
Cybin Acquires Entheon’s DMT Trial, Numi’s Novamind Acq. Complete, Bad News for MindMed and More
This week in psychedelic business news: Cybin acquires a Phase…
Psychedelic Crossword Puzzle: Name the Psychedelic Pioneer
This psychedelic puzzle requires you to be a skilled psychedelic detective and investigate history more thoroughly.
atai Life Sciences Q2 Conference Call and Questions & Answer Period: BIG NEWS for Psychedelic Stocks
What’s up psychedelic stocks investors?!? Today marked atai Life Science’s (Nasdaq: atai) first-ever conference call, for Quarter 2, 2021. In the conference call, atai Life Sciences gave updates on their varying projects, ranging from attempting to treat depression, to cognitive impairment associated with schizophrenia. They also give insights on atai’s digital medicines division and answer investor’s questions at the end of the call.
This Peter Thiel-backed psychedelic therapies company is fighting for the title of the most advanced psychedelic stock. With 10+ different projects under their belt, atai is one of the most exciting companies to keep an eye on in the industry.
This conference call can help investors answer the questions: is atai stock a good investment? Will atai go up? Are psychedelic stocks / shroom stocks good investments? Can psychedelics heal depression? Can psychedelics be used for mental health?
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Check out our website: thepsychedelicinvestor.com
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
#atai #ataiLifeSciences #PsychedelicStocks
Journeying Beyond the Self: Timothy Leary’s 5 Levels of Psychedelic Experience
The psychedelic experience can be downright tantalizing for the unprepared folk. While most trips can lead to profound feelings of interconnectedness and life-changing introspective or philosophical insights, without preparation, some people may increase their chances of a tantalizing bad trip.
One way to reduce the possibility of a challenging trip is to get an introduction of Timothy Leary’s five levels of the psychedelic experience.
Newsmax Anchor Blames Aaron Rodgers Injury on Psychedelic Drugs
A conservative media personality uses the quarterback’s injury as an excuse to rant against ayahuasca, which he deems “a crummy substitute for God.”
Is MindMed Expanding to PSILOCYBIN? (BIG MMED / MMEDF Stock NEWS)
In today’s episode, we will be covering some Massive MindMed news that broke on January 14th that lead me to believe that MindMed might be expanding to psilocybin.
Mindmed stock, MMED on the Canadian NEO market, and MMEDF on the American OTC market led with a press release entitled “MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience”. MindMed revealed that the company has added a scientist named Robert Barrow as their Chief Development Officer.
Tucked away in this news release about a hiring decision is a quote which points to a future MindMed project
And that project will be researching the effects of Psilocybin
So up until now, MindMed has focused all their phase 2 trials on LSD and 18-MC, which is a derivative of Ibogaine, while leaving treating maladies with psilocybin to other companies like Compass Pathways (NASDAQ:CMPS).
So, Barrow is bringing with him to MindMed intimate knowledge about the efficacy of psilocybin in treating MDD, as well as dosing data and regime set up.
MindMed (MMED/MMEDF) has some phase 1 trials looking at the safety of psilocybin in conjunction with the Liechti Lab at the University Hospital Basel
and is also comparing psilocybin to LSD in a phase 1 trial. MindMed also has a licence to test psilocybin. However, MindMed has yet to start a trial specifically looking at psilocybin as a medicine..
So does this mean that MindMed’s hiring decision is related to the company’s plans on expanding their clinical trial pipeline to include a psilocybin treatment, sometime in the future? If that speculation turns out to be true, that decision will further expand MindMed’s potential product pipeline as well as the MindMed stock.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://mindmed.co/wp-content/uploads/2020/11/investor-deck.pdf
https://www.businesswire.com/news/home/20190905005528/en/Usona-Institute-Clinical-Trial-Psilocybin-Major-Depressive
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MMED #MMEDF